| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| CAGR | 10.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Human Respiratory Syncytial Virus Treatment Market Analysis
The Human Respiratory Syncytial Virus Treatment Market is expected to register a CAGR of 10% during the forecast period.
COVID-19 had a notable impact on the human respiratory syncytial virus treatment market. The viral interference can alter the pattern and dynamics of syncytial virus infection. For instance, as per the article published in December 2021 in PubMed, the COVID-19 pandemic drastically changed the epidemiology of other viral respiratory infections including RSV in both children and adults. As per the same source, the rhinovirus could compete with other respiratory viruses and change the epidemic dynamics. Thus, during the pandemic, the delayed onset of the infection, as well as the limited number of cases reported, could be attributed to viral interference. However, as the restrictions are eased, the human respiratory syncytial virus treatment market is expected to witness growth in the coming years due to the rise in the prevalence of respiratory syncytial virus and the increase in technological advances in treatment.
Factors such as the rise in the prevalence of RSV and the increase in government support and funding for the development of RSV treatment are expected to drive market growth. For instance, as per the article published in November 2022 in MedRxiv, there were significant racial and ethnic disparities in the peak RSV infection rate during 2010-2021 and the disparities were further exacerbated in 2022 with a peak incidence rate in black and Hispanic children 2-3 times that in white children. Among RSV-infected children in 2022, 19.2% had prior documented COVID-19 infection, significantly higher than the 9.7% among uninfected children, suggesting that prior COVID-19 could be a risk factor for RSV infection or that there are common risk factors for both viral infections. Furthermore, as per the CDC's October 2022 update, in the 2022-2023 season, the overall rate of RSV-associated hospitalization was 43.4 per 100,000 people. Thus, such a rise in RSV infections is likely to increase the demand for proper treatment and thereby drive market growth.
Moreover, the increase in research and development and pipeline assets for RSV treatment by the key players are expected to promote market growth over the forecast period. For instance, in October 2022, GSK's older adult respiratory syncytial virus (RSV) vaccine candidate showed a 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in the pivotal trial. The data presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with a favorable safety profile.
Hence, a rise in RSV infection and an increase in pipeline assets by the key players are expected to increase the growth of the studied market over the forecast period. However, less availability of safe and effective antiviral drugs can hinder the market growth over the study period.
Human Respiratory Syncytial Virus Treatment Market Trends
Parenteral Segment is Expected to Witness a Healthy Growth in the Market Over the Forecast Period
The parenteral segment is expected to witness growth in the studied market due to the increase in the development of vaccines against RSV and the rise in the prevalence of RSV diseases across the globe. For instance, as per the article published in December 2022 in Nature journal, researchers had developed a vaccine containing RSV particles that were chemically inactivated so that the virus couldn't replicate. Rather than attempting to create a vaccine from an inactivated virus, researchers aimed to create a protein-based vaccination in which an isolated component of the virus, such as a surface protein, is used to stimulate a protective immune response. Hence, such an increase in research development of the parenteral route of RSV treatment is expected to boost segment growth.
Moreover, many of the key players receiving the approvals and different designations for their clinical assets for RSV treatment are expected to drive the market growth. For instance, in March 2022, a Pfizer vaccine candidate received Breakthrough Therapy Designation from the FDA for the prevention of RSV-associated lower respiratory tract disease in infants up to six months of age by active immunization of pregnant women. Further, in April 2022, ModernaTX, Inc. sponsored a clinical study to evaluate the impact of co-administered influenza vaccine on the immune response to RSV-A and to evaluate the impact of the co-administered RSV vaccine on the immune response to influenza.
Hence, a rise in demand for the parenteral route of administration in RSV infection and an increase in pipeline assets by the key players are expected to drive the growth of the studied segment over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the studied market due to the increase in RSV infection, rise in research and development, presence of key players, and increase in healthcare expenditure in the region. For instance, in November 2022, GSK Canada filed a New Drug Submission (NDS) to Health Canada for its respiratory syncytial virus (RSV) older adult vaccine candidate. GSK'S RSV older adult vaccine candidate has the potential to be the first vaccine available to help protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
Similarly, In November 2022, Pfizer publicized the positive top-line data of phase 3 global maternal immunization trial for its bivalent respiratory syncytial virus (RSV) vaccine candidate. Vaccine efficacy of 81.8% was observed against severe medically attended lower respiratory tract illness due to RSV in infants from birth through the first 90 days of life with high efficacy of 69.4% demonstrated through the first six months of life. Hence, such clinical studies by the major players are expected to increase the market growth of RSV therapies in the region. Moreover, as per the November 2022 CDC health advisory and media briefing, the incidence of respiratory syncytial virus (RSV) is increasing in 8 out of 10 public health regions in the U.S. (all except the Southeast and South-Central parts of the country). At that time, some regions were already nearing levels typically observed during the virus's seasonal peak months of December or January. Hence, such a rise in the prevalence of RSV in the studied region is expected to drive market growth over the forecast period.
Hence, due to the rise in RSV infection and an increase in pipeline assets by the key players, North America is expected to hold a significant market share over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Human Respiratory Syncytial Virus Treatment Industry Overview
The human respiratory syncytial virus treatment market is fragmented in nature and consists of several major players. Some of the companies which are currently dominating the market are AstraZeneca, AbbVie Inc, Merck & Co, GSK plc, and Bausch Health Companies Inc.
Human Respiratory Syncytial Virus Treatment Market Leaders
-
Ā AbbVie Inc
-
Merck & Co
-
AstraZeneca
-
GSK plc
-
Bausch Health Companies Inc.
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Human Respiratory Syncytial Virus Treatment Market News
- In January 2023, AstraZeneca's Biologics License Application (BLA) for nirsevimab was accepted for review by the US Food and Drug Administration (FDA) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants entering or during their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
- In December 2022, FDA accepted for priority review a Biologics License Application (BLA) for Pfizer's respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, as submitted for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Human Respiratory Syncytial Virus Treatment Industry Segmentation
As per the scope of the report, respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. The Human Respiratory Syncytial Virus Treatment Market is Segmented by Route of Administration (Oral, Parenteral), Treatment Type (Supportive Care, Hospital Care), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The market report also covers the estimated market sizes and trends for 17 different countries across the major regions globally. The report offers the value (in USD million) for all the above segments.
| By Route of Administration | Oral | ||
| Parenteral | |||
| By Treatment Type | Supportive Care | ||
| Hospital Care | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Human Respiratory Syncytial Virus Treatment Market Research FAQs
What is the current Human Respiratory Syncytial Virus Treatment Market size?
The Human Respiratory Syncytial Virus Treatment Market is projected to register a CAGR of 10% during the forecast period (2025-2030)
Who are the key players in Human Respiratory Syncytial Virus Treatment Market?
AbbVie Inc, Merck & Co, AstraZeneca, GSK plc and Bausch Health Companies Inc. are the major companies operating in the Human Respiratory Syncytial Virus Treatment Market.
Which is the fastest growing region in Human Respiratory Syncytial Virus Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Human Respiratory Syncytial Virus Treatment Market?
In 2025, the North America accounts for the largest market share in Human Respiratory Syncytial Virus Treatment Market.
What years does this Human Respiratory Syncytial Virus Treatment Market cover?
The report covers the Human Respiratory Syncytial Virus Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Human Respiratory Syncytial Virus Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Human Respiratory Syncytial Virus Treatment Industry Report
Statistics for the 2025 Human Respiratory Syncytial Virus Treatment market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Human Respiratory Syncytial Virus Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
